Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Medinice's interest expense for the
three
months ended in Mar. 2026 was zł -0.03 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.07 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Medinice's Operating Income for the
three
months ended in Mar. 2026 was zł -1.20 Mil. Medinice's Interest Expense for the
three
months ended in Mar. 2026 was zł -0.03 Mil.
Medinice did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Medinice (WAR:ICE) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Medinice's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as
Medinice did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Medinice Interest Expense Historical Data
* Premium members only.
The historical data trend for Medinice's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinice (WAR:ICE) has a Interest Expense of zł-0.07 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Medinice and its competitors.
Is Medinice's Interest Expense too high?
Medinice's current Interest Expense is zł-0.07 Mil. Overall, Medinice has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's Interest Expense compare to ABT and SYK?
Medinice's Interest Expense of zł-0.07 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Medical Devices & Instruments company?
A good Interest Expense depends on the Medical Devices & Instruments industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Medinice and its competitors. Medinice's current Interest Expense is zł-0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł71.60 — trading 7132.3% above its estimated fair value. The current Interest Expense is zł-0.07 Mil. Medinice's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Medinice (WAR:ICE), the current Interest Expense is zł-0.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinice (WAR:ICE) Overvalued in 2026?
Based on GuruFocus' analysis, Medinice stock appears to be overvalued.
The current stock price of zł71.60 is trading 7132.3% above its estimated GF Value™ of zł0.99.
GuruFocus considers Medinice to be Significantly Overvalued.
Key valuation signals for WAR:ICE:
Interest Expense: zł-0.07 Mil
GF Value™: zł0.99 vs. price of zł71.60 (7132.3% above fair value)
No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
25GF Score
Get the complete analysis for WAR:ICE
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ICE has been successfully added to your 
